Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

ClearPoint Neuro Announces First Procedure Utilizing ClearPoint 2.0 Software

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, reported the first utilization in Europe of its Version 2.0 software, together with the ClearPoint Neuro Navigation System, at Rigshospitalet in Copenhagen, Denmark. The procedure, which took place last week, also represents the first European site to use the ClearPoint System under live MRI guidance for navigation of a laser catheter in the brain.

Recommended AI News: iCIMS Achieves Leading International Privacy and Information Security Certifications

“ClearPoint offers a stereotactic system based on MRI localization with an MRI compatible frame. My clear impression, after my first-time experience, is that the system offers superior accuracy of the stereotactic procedure as compared to our standard frame with CT localization,” stated Rune Rasmussen, MD, PhD, Head of Stereotactics at Rigshospitalet. “With a small tumor target and a very challenging anatomy and vasculature, having the ability to perform this case with ClearPoint under live MRI guidance provided us with great confidence that our placement of the catheter was no less than optimal. An additional advantage is the on-site stereotactic support from very competent representatives.”

Related Posts
1 of 33,435

Recommended AI News: Convene and Eden Health Expand Partnership to Include Access to Healthcare for WorkPlace Members

“We were delighted to support the talented team at Rigshospitalet during the first European procedure with our latest ClearPoint System,” commented Matt Rabon, Clinical and Business Development Manager, EMEA. “Expanding into Europe fulfills our strategic mission to become the premier global therapy delivery partner in the Neuro space. We have hired a strong team and are executing against the strategy we put into motion over the past year. We are looking forward to supporting additional installations across the EMEA region in the months ahead as we expand our reach and access to the ClearPoint portfolio of products and services. As our footprint expands into these new geographies, we will be able to attract even more biologics and drug delivery partners who are interested in enrolling trial patients outside of the U.S.”

Recommended AI News: Spectrio Acquires ScreenScape

Leave A Reply

Your email address will not be published.